Children’s Hospital of Philadelphia
Dr. Jane Minturn's research is focused on developing personalized and targeted therapeutics in tumors of the nervous system and understanding the late effects of our therapies in long-term survivors.
As part of our approach to identifying new treatments for children with brain tumors, we are members of the multi-institutional Pacific Pediatric Neuro-Oncology Consortium (PNOC) and a Children's Oncology Group (COG) Phase 1 Institution. These groups are involved in early phase clinical trials for relapsed and refractory brain tumors, with a particular focus on testing new, targeted treatments in children with brain tumors.
Our Children's Hospital team has partnered with drug development groups, and we are rapidly identifying drugs that show promise in patients with brain tumors who have no other curable option. There is a sense of urgency in our group — working collaboratively with laboratory scientists and drug development companies on rational, biologically-based therapies.
Atypical teratoid/rhabdoid tumor (AT/RT)
Central nervous system (CNS) atypical teratoid/rhabdoid tumor (AT/RT) is a very rare, fast-growing tumor of the brain and spinal cord. It usually occurs in children aged three years and younger, although it can occur in older children and adults. About half of these tumors form in the cerebellum
Low-Grade astrocytomas are the most common cancer of the central nervous system in children. They represent a heterogeneous group of tumors that can be discovered anywhere within the brain or spinal cord. Although surgical resection may be curative, up to 20% of children still suffer from the eff